Estudio observacional sobre tratamiento trombolítico del infarto cerebral agudo en pacientes mayores y menores de 80 años: experiencia de un hospital en Bogotá, Colombia, 2007-2014

dc.contributor.authorHernán Bayona
dc.contributor.authorCamilo Andrés Díaz-Cruz
dc.contributor.authorLina Góez-Mogollón
dc.contributor.authorNicolás Useche-Gómez
dc.contributor.authorMaría Camila Valencia-Mendoza
dc.contributor.authorValerie Jeanneret López
dc.contributor.authorAndrés Díaz-Campos
dc.contributor.authorMaría Camila Valencia-Mendoza
dc.contributor.authorUniversidad de los Andes
dc.contributor.authorValerie Jeanneret López
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:16:12Z
dc.date.available2026-03-22T15:16:12Z
dc.date.issued2017
dc.descriptionCitaciones: 3
dc.description.abstractBackground: we depict the experience with the use of thrombolysis for acute ischemic stroke in a tertiary center in South America. Objective: to describe the main outcomes in our population of patients aged less and older than 80 years treated with recombinant tissue plasminogen activator. Materials and Methods: retrospective observational study. We described the main variables and the difference in outcome accounting for age. Results: 70 patients were included. 51.4% of the patients were women, 22.8% were older than 80 years. The average window time was 70 minutes and the average door-to-needle time was 90 minutes. Hypertension, dyslipidemia and previous stroke were the most common risk factors. Favorable outcome Modified Rankin Scale 2 was present in 25% of the patients older than 80 years and 53.7% in the population younger than 80 years (p=0.009). Mortality was present in 31.2% of the patients older than 80 years and in 5.5% of the patients younger than 80 years (p=0.005). Symptomatic intra-cerebral hemorrhage was found in 6.25% of the patients older than 80 years (p=0.65), compared to 3.7% in the younger than 80 years. Conclusions: we found that intravenous thrombolysis still had benefit in people older than 80 years. Significant differences in symptomatic intra-cerebral hemorrhage were not found, however, a greater mortality in patients older than 80 years was. These findings of our experience of recombinant tissue plasminogen activator use in real life are consistent with other latinamerican publications. MD.UIS.
dc.identifier.doi10.18273/revmed.v30n3-2017002
dc.identifier.urihttps://doi.org/10.18273/revmed.v30n3-2017002
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/51381
dc.language.isoes
dc.relation.ispartofRevista Médicas UIS
dc.sourceUniversidad de Los Andes
dc.subjectMedicine
dc.subjectHumanities
dc.titleEstudio observacional sobre tratamiento trombolítico del infarto cerebral agudo en pacientes mayores y menores de 80 años: experiencia de un hospital en Bogotá, Colombia, 2007-2014
dc.typearticle

Files